Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.

Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G

Calcified tissue international9 Jul 2016Cited by 39 (Europe PMC)

PMID27395059PMCIDPMC5055567DOI10.1007/s00223-016-0171-1PepBankPUB-27395059

Summary

Abaloparatide is a novel, potent and selective activator of parathyroid hormone receptor 1 (PTHR1) under clinical development for the treatment of osteoporosis. We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats. After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg. Sham-operated control rats (n = 24) received vehicle. Areal bone mineral density (aBMD) of the lumbar spine (L4), total femur and femur diaphysis was measured at baseline and after 6 weeks of treatment. Femur and vertebral bone architecture and mechanical properties were assessed at the end of the treatment phase. At baseline, OVX-Veh rats exhibited significantly lower aBMD relative to Sham controls. Treatment of OVX rats with abaloparatide at 5 or 20 µg/kg/day increased aBMD dose-dependently in the lumbar spine, total femur and femur diaphysis to levels exceeding OVX-Veh or Sham controls. The abaloparatide 5 and 20 µg/kg groups had improved trabecular microarchitecture relative to OVX vehicle, with trabecular BV/TV exceeding OVX-Veh control values by 57 and 78 % (respectively) at the lumbar spine, and by 145 and 270 % at the distal femur. Femur diaphyseal cortical volume and thickness were significantly greater in the abaloparatide 20 µg/kg group relative to OVX vehicle or Sham controls. Bone strength parameters of the femur diaphysis, femur neck and L4 vertebra were significantly improved in the OVX-ABL groups relative to OVX-Veh controls. Bone mass-strength relationships and estimated intrinsic strength properties suggested maintained or improved bone quality with abaloparatide. These data demonstrate skeletal restoration via abaloparatide treatment of osteopenic OVX rats, in association with improved trabecular microarchitecture, cortical geometry and bone strength at sites that have clinical relevance in patients with osteoporosis.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

18 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased lumbar spine aBMD above OVX vehicle levels in a dose-dependent manner.
In plain wordsIn rats, abaloparatide increased lumbar spine bone density above vehicle levels.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar spine aBMD
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Treatment of OVX rats with abaloparatide at 5 or 20 µg/kg/day increased aBMD dose-dependently in the lumbar spine, total femur and femur diaphysis to levels exceeding OVX-Veh or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505901
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased lumbar spine aBMD above sham control levels.
In plain wordsIn rats, abaloparatide increased lumbar spine bone density above sham control levels.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar spine aBMD
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
Sham controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Treatment of OVX rats with abaloparatide at 5 or 20 µg/kg/day increased aBMD dose-dependently in the lumbar spine, total femur and femur diaphysis to levels exceeding OVX-Veh or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505902
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased total femur aBMD above OVX vehicle levels.
In plain wordsIn rats, abaloparatide increased total femur bone density above vehicle levels.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal femur aBMD
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Treatment of OVX rats with abaloparatide at 5 or 20 µg/kg/day increased aBMD dose-dependently in the lumbar spine, total femur and femur diaphysis to levels exceeding OVX-Veh or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505903
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased total femur aBMD above sham control levels.
In plain wordsIn rats, abaloparatide increased total femur bone density above sham control levels.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTotal femur aBMD
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
Sham controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Treatment of OVX rats with abaloparatide at 5 or 20 µg/kg/day increased aBMD dose-dependently in the lumbar spine, total femur and femur diaphysis to levels exceeding OVX-Veh or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505904
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased femur diaphysis aBMD above OVX vehicle levels.
In plain wordsIn rats, abaloparatide increased femur shaft bone density above vehicle levels.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur diaphysis aBMD
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Treatment of OVX rats with abaloparatide at 5 or 20 µg/kg/day increased aBMD dose-dependently in the lumbar spine, total femur and femur diaphysis to levels exceeding OVX-Veh or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505905
06AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased femur diaphysis aBMD above sham control levels.
In plain wordsIn rats, abaloparatide increased femur shaft bone density above sham control levels.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur diaphysis aBMD
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
Sham controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Treatment of OVX rats with abaloparatide at 5 or 20 µg/kg/day increased aBMD dose-dependently in the lumbar spine, total femur and femur diaphysis to levels exceeding OVX-Veh or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505906
07AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased lumbar trabecular BV/TV by 57% relative to vehicle.
In plain wordsIn rats, abaloparatide increased lumbar trabecular bone volume relative to vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar trabecular BV/TV
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Measurements
BV/TV increase
57%
lumbar spine; 5 µg/kg
Source sentences
Summary
The abaloparatide 5 and 20 µg/kg groups had improved trabecular microarchitecture relative to OVX vehicle, with trabecular BV/TV exceeding OVX-Veh control values by 57 and 78 % (respectively) at the lumbar spine, and by 145 and 270 % at the distal femur.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505907
08AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased lumbar trabecular BV/TV by 78% relative to vehicle.
In plain wordsIn rats, abaloparatide increased lumbar trabecular bone volume relative to vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar trabecular BV/TV
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Measurements
BV/TV increase
78%
lumbar spine; 20 µg/kg
Source sentences
Summary
The abaloparatide 5 and 20 µg/kg groups had improved trabecular microarchitecture relative to OVX vehicle, with trabecular BV/TV exceeding OVX-Veh control values by 57 and 78 % (respectively) at the lumbar spine, and by 145 and 270 % at the distal femur.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505908
09AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased distal femur trabecular BV/TV by 145% relative to vehicle.
In plain wordsIn rats, abaloparatide increased distal femur trabecular bone volume relative to vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseDistal femur trabecular BV/TV
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Measurements
BV/TV increase
145%
distal femur; 5 µg/kg
Source sentences
Summary
The abaloparatide 5 and 20 µg/kg groups had improved trabecular microarchitecture relative to OVX vehicle, with trabecular BV/TV exceeding OVX-Veh control values by 57 and 78 % (respectively) at the lumbar spine, and by 145 and 270 % at the distal femur.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505909
10AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased distal femur trabecular BV/TV by 270% relative to vehicle.
In plain wordsIn rats, abaloparatide increased distal femur trabecular bone volume relative to vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseDistal femur trabecular BV/TV
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Measurements
BV/TV increase
270%
distal femur; 20 µg/kg
Source sentences
Summary
The abaloparatide 5 and 20 µg/kg groups had improved trabecular microarchitecture relative to OVX vehicle, with trabecular BV/TV exceeding OVX-Veh control values by 57 and 78 % (respectively) at the lumbar spine, and by 145 and 270 % at the distal femur.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505910
11AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased femur diaphyseal cortical volume versus OVX vehicle.
In plain wordsIn rats, abaloparatide increased femur cortical volume versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur cortical volume
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Femur diaphyseal cortical volume and thickness were significantly greater in the abaloparatide 20 µg/kg group relative to OVX vehicle or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505911
12AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased femur diaphyseal cortical volume versus sham controls.
In plain wordsIn rats, abaloparatide increased femur cortical volume versus sham controls.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur cortical volume
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
Sham controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Femur diaphyseal cortical volume and thickness were significantly greater in the abaloparatide 20 µg/kg group relative to OVX vehicle or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505912
13AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased femur diaphyseal cortical thickness versus OVX vehicle.
In plain wordsIn rats, abaloparatide increased femur cortical thickness versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur cortical thickness
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Femur diaphyseal cortical volume and thickness were significantly greater in the abaloparatide 20 µg/kg group relative to OVX vehicle or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505913
14AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased femur diaphyseal cortical thickness versus sham controls.
In plain wordsIn rats, abaloparatide increased femur cortical thickness versus sham controls.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur cortical thickness
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
Sham controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Femur diaphyseal cortical volume and thickness were significantly greater in the abaloparatide 20 µg/kg group relative to OVX vehicle or Sham controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505914
15AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide improved femur diaphysis strength parameters versus OVX vehicle.
In plain wordsIn rats, abaloparatide improved femur shaft strength parameters versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur diaphysis strength parameters
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Bone strength parameters of the femur diaphysis, femur neck and L4 vertebra were significantly improved in the OVX-ABL groups relative to OVX-Veh controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505915
16AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, bone mass-strength relationships and estimated intrinsic strength suggested maintained or improved bone quality with abaloparatide.
In plain wordsIn rats, bone measurements suggested maintained or improved bone quality with abaloparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
MixedBone quality
Study
ratn: not reported in source
ovariectomized osteopenic rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Bone mass-strength relationships and estimated intrinsic strength properties suggested maintained or improved bone quality with abaloparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505916
17AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide improved femur neck strength parameters versus OVX vehicle.
In plain wordsIn rats, abaloparatide improved femur neck strength parameters versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
Increasefemur neck strength parameters
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Bone strength parameters of the femur diaphysis, femur neck and L4 vertebra were significantly improved in the OVX-ABL groups relative to OVX-Veh controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505917
18AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide improved L4 vertebra strength parameters versus OVX vehicle.
In plain wordsIn rats, abaloparatide improved L4 vertebra strength parameters versus vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseL4 vertebra strength parameters
Study
ratn: not reported in source
ovariectomized osteopenic rats
Comparator
OVX vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
5 or 20 µg/kg/day · subcutaneous · 6 weeksAs given in this study (rat).
Source sentences
Summary
Bone strength parameters of the femur diaphysis, femur neck and L4 vertebra were significantly improved in the OVX-ABL groups relative to OVX-Veh controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats.
Summary · context
After 8 weeks of post-surgical bone depletion (baseline), OVX rats (n = 20-21/group) received daily subcutaneous vehicle (OVX-Veh) or abaloparatide at 5 or 20 µg/kg.
Show in the study text Report a problemFND-2739505918

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.

Summary

Results from this study18

Version history

Subjects

Publication types

MeSH terms

Keywords